Loretta Brunetti who is a volunteer at Cancer Treatment Centers of America in Tulsa was awarded a Daily Point of Light for the time and energy she dedicates to the hospital. The high-spirited 77-year-old has made it her life’s passion to giving back to cancer patients.
Watching our loved ones in a medical crisis is hard enough. But when you are an oncology nurse and your loved one passes away from the disease, it can be very difficult to return to work. Mena Evans, RN, BSN, OCN, who recently celebrated her 25th year at Cancer Treatment Centers of America in Tulsa, can relate.
Alan Tan, MD, Clinical Research Medical Director & Medical Oncologist and Hematologist at Cancer Treatment Centers of America in Phoenix is using an oncolytic virus to battle melanoma by injecting T-VEC directly into melanoma lesions.
Ankur Parikh, DO, Medical Director of Precision Medicine at Cancer Treatment Centers of America® (CTCA), recently authored a commentary in STAT discussing the importance of extending promising cancer treatments to older patients:
Alan Tan, MD, Clinical Research Medical Director & Medical Oncologist and Hematologist at Cancer Treatment Centers of America in Phoenix, explains how medical oncologists are using a genetically modified herpes virus to treat cancer. T-VEC is an FDA-approved oncolytic virus therapy, which uses the virus to infect the cancer cells while avoiding healthy cells.
Dr. Kevin Tulipana, Medical Director of Hospital Medicine at Cancer Treatment Centers of America in Tulsa, explains why it’s good to know your family’s health history. His father was diagnosed with pancreatic cancer at the age of 57 and passed away three years later.
Patrick Nobles, RN at Cancer Treatment Centers of America in Tulsa, recently received a DAISY Award for providing extraordinary, compassionate and skillful care to patients. He was inspired by his mother to become a nurse and has worked at the Tulsa hospital for six years.
Dennis Citrin, MB ChB, PhD, Medical Oncologist at Cancer Treatment Centers of America® in Chicago, comments on a recent phase III randomized clinical trial concluding that six months of Herceptin use for patients with HER2+ breast cancer is “non-inferior” to the standard 12-month use.
Pete Govorchin, Chief Operating Officer at Cancer Treatment Centers of America® (CTCA) in Chicago, and Julian Schink, MD, Chief of Gynecologic Oncology at CTCA®, talk about the new CTCA Outpatient Care Center in Downtown Chicago on Windy City Live. They also invited the general public to come celebrate cancer survivors on June 1 at the Tribune Plaza in Chicago.
Cancer Treatment Centers of America (CTCA) today announced it is enrolling patients in a clinical study designed to evaluate a potential new treatment option for patients with HER2-positive breast cancer.